When additional human tumor cell lines were tested, such as multiple myeloma, breast carcinoma, or lymphoma (all of which displayed greatly varying levels of COX-2 expression), very similar outcomes were observed (not shown). This evidence concerns the gene PTGS2 and neoplasm.